These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10995998)

  • 1. Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
    Hołowiecki J; Wojciechowska M; Giebel S; Krawczyk-Kuliś M; Wojnar J; Kachel L; Kata D; Markiewicz M
    Transplant Proc; 2000 Sep; 32(6):1412-5. PubMed ID: 10995998
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
    Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
    J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
    Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.
    McQuaker IG; Haynes AP; Stainer C; Anderson S; Russell NH
    Br J Haematol; 1997 Jul; 98(1):228-33. PubMed ID: 9233591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.
    Ozkan HA; Bal C; Gulbas Z
    Eur J Haematol; 2014; 92(5):390-7. PubMed ID: 24400988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
    Bishton MJ; Lush RJ; Byrne JL; Russell NH; Shaw BE; Haynes AP
    Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
    Pocali B; De Simone M; Annunziata M; Palmieri S; D'Amico MR; Copia C; Viola A; Mele G; Schiavone EM; Ferrara F
    Leuk Lymphoma; 2004 Aug; 45(8):1605-9. PubMed ID: 15370212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
    Copelan EA; Ceselski SK; Ezzone SA; Lasky LC; Penza SL; Bechtel TP; Klein JL; Hehmeyer DM; Scholl MD; Marshall DD; Elder PJ; Risley GL; Avalos BR
    J Clin Oncol; 1997 Feb; 15(2):759-65. PubMed ID: 9053502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
    Kanfer EJ; McGuigan D; Samson D; Abboudi Z; Abrahamson G; Apperley JF; Chilcott S; Craddock C; Davis J; MacDonald C; Macdonald D; Olavarria E; Philpott N; Rustin GJ; Seckl MJ; Sekhar M; Stern S; Newlands ES
    Br J Cancer; 1998 Oct; 78(7):928-32. PubMed ID: 9764585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
    Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
    Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
    Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Various Hematopoietic Stem Cell Mobilization Regimens in Patients with Lymphoma and Myeloma.
    Yilmaz Ü; Salim O; Yücel OK; Iltar U; Ündar L
    Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma.
    Straka C; Hebart H; Adler-Reichel S; Werding N; Emmerich B; Einsele H
    Oncology; 2003; 65 Suppl 2():94-8. PubMed ID: 14586157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.